Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Jan;118(1):99-104.
doi: 10.1016/j.radonc.2015.12.018. Epub 2016 Jan 2.

Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer

Jeffrey V Brower  1 , Jeffrey D Forman  2 , Patrick A Kupelian  3 , Daniel G Petereit  4 , Vinai Gondi  5 , Colleen A Lawton  6 , Nick Anger  1 , Sandeep Saha  7 , Rick Chappell  7 , Mark A Ritter  8
Affiliations
Clinical Trial

Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer

Jeffrey V Brower et al. Radiother Oncol. 2016 Jan.

Abstract

Objective: This multi-institutional phase I/II trial explored patient-assessed tolerance of increasingly hypofractionated (HPFX) radiation for low/intermediate risk prostate cancer.

Methods: 347 patients enrolled from 2002 to 2010. Three increasing dose-per-fraction schedules of 64.7 Gy/22 fx, 58.08 Gy/16 fx and 51.6 Gy/12 fx were each designed to yield equivalent predicted late toxicity. Three quality of life (QoL) surveys were administered prior to treatment and annually upto 3 years.

Results: Bowel QoL data at 3years revealed no significant difference among regimens (p=0.469). Bowel QoL for all regimens declined transiently, largely recovering by three years, with only the 22 fraction decrement reaching significance. Bladder outcomes at 3 years were comparable (p=0.343) although, for all patients combined, a significant decline was observed from the baseline (p=0.008). Spitzer quality of life data revealed similarly excellent, 3-year means (p=0.188). International erectile function data also revealed no significant differences at 3 years although all measures except intercourse satisfaction worsened post-treatment.

Conclusions: Three-year QoL changes for bowel, bladder and SQLI were modest and similar for 3 HPFX regimens spanning 2.94-4.3 Gy per fraction. These favorable patient-scored outcomes demonstrate the safety and tolerability of such regimens and may be leveraged to support further implementation of mild to moderately hypofractionated radiotherapy in the setting of low and intermediate-risk prostate cancer.

Keywords: Hypofractionation; Prostate; Quality of life; SBRT.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest Notification: Conflict of Interest: none

Figures

Figure 1
Figure 1
A, B: QoL metrics from baseline to year three. A. Bowel and B. Bladder * Indicates statistically significant change from baseline. C, D: Physician scored toxicities. C. Bowel and D. Bladder
Figure 2
Figure 2
Spitzer Quality of Life change from baseline to year three
See this image and copyright information in PMC

References

    1. Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, et al. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83:617–623. - PubMed
    1. Pervez N, Krauze AV, Yee D, Parliament M, Mihai A, Ghosh S, et al. Quality-of-life outcomes in high-risk prostate cancer patients treated with helical tomotherapy in a hypofractionated radiation schedule with long-term androgen suppression. Curr Oncol. 2012;19:e201–210. - PMC - PubMed
    1. Katz A, Ferrer M, Suarez JF, Multicentric Spanish Group of Clinically Localized Prostate C Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer. Radiat Oncol. 2012;7:194. - PMC - PubMed
    1. Norkus D, Karklelyte A, Engels B, Versmessen H, Griskevicius R, De Ridder M, et al. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiat Oncol. 2013;8:206. - PMC - PubMed
    1. Jereczek-Fossa BA, Santoro L, Zerini D, Fodor C, Vischioni B, Dispinzieri M, et al. Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients. J Urol. 2013;189:2099–2103. - PubMed

Publication types